
    
      In expansion stage part 1, up to 20 advanced sold tumor subjects will be investigated the
      safety profiled and antitumor effect of OPB-51602 at the recommended dose for 3 weeks per
      cycleï¼ˆ2 weeks treatment and 1 week washout). In the expansion stage part 2, a maximum of 20
      subjects with Non-small cell lung cancer (NSCLC), Melanoma or Gastrointestinal Stromal Tumor
      (GIST) will be treated until an investigational Medicinal product (IMP) efficacious case can
      be found. subject dosing will be started on Day 1 without 2-day treatment free interval and
      continued until Day 28 at recommend dose (4mg) first in cycle 1. After safety and
      tolerability are confirmed, same subjects will be treated at the MTD(5mg) from cycle 2
      onwards as a once-daily oral dose for 4 weeks per cycle to obtain additional information
      about safety, tolerability and antitumor activity of OPB-51602
    
  